Table 4.
Logistic regression analysis for predicting the need for mechanical ventilation in the study groups (N = 225)
| Variables | Adjusted modela | p value | |
|---|---|---|---|
| OR | 95% CI | ||
| Constant | 0.002 | < 0.001* | |
| Age (years) | 1.053 | 1.019–1.088 | 0.002* |
| Severe/critical COVID-19 (vs moderate) | 69.00 | 10.43–456.7 | < 0.001* |
| Comorbidities | |||
| Diabetes mellitus (vs No) | 0.718 | 0.326–1.580 | 0.410 |
| Hypertension (vs No) | 2.414 | 1.066–5.466 | 0.035* |
| Established cardiovascular disease (vs No) | 3.179 | 0.903–11.19 | 0.072 |
| Study groups (vs non-ASA and non-ENX) | |||
| Acetylsalicylic acid alone | 1.095 | 0.130–8.791 | 0.932 |
| Enoxaparin alone | 0.276 | 0.051–1.391 | 0.125 |
| Both acetylsalicylic acid and enoxaparin | 0.032 | 0.004–0.226 | 0.001* |
Variables entered on step 1: Age (y), COVID-19 Severity (severe/critical vs moderate), diabetes mellitus (Y/N), hypertension (Y/N), established cardiovascular disease (Y/N), and study groups (vs non-acetylsalicylic acid and non-anticoagulant)
ASA acetylsalicylic acid, CI confidence interval, ENX enoxaparin, OR odds ratio
*Statistically significant p value (< 0.05)
aBinary Logistic Regression Model: Hosmer and Lemeshow χ2 (df) = 6.969 (8), p = 0.540; Negelkerke R Square = 0.541; Overall correct classification = 79.1%